ERBB2 and breast cancer: As a second mechanistic explanation for the survival benefit of metformin in patients with hormone-responsive and HER2-positive breast cancer, metformin may increase the efficacy of systemic treatments for this subtype of tumors by overcoming resistance to these therapies.